Citation Impact
Citing Papers
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
2015 StandoutNobel
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
2010
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
2003 StandoutNobel
Tumor-specific Th17-polarized cells eradicate large established melanoma
2008
Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
2009
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
2012
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
2002
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
2001
Combinatorial Cancer Immunotherapy
2006
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
2014 Standout
New Technologies for Glycomic Analysis: Toward a Systematic Understanding of the Glycome
2011
Inflammation and cancer
2002 StandoutNature
A view on drug resistance in cancer
2019 StandoutNature
Tumor adaptation and resistance to RAF inhibitors
2013
Multistage Nanoparticles for Improved Delivery into Tumor Tissue
2012 StandoutNobel
Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40
1999
Active immunization against cancer with dendritic cells: The near future
2001 StandoutNobel
Regulatory T Cells
2000 StandoutNobel
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens
2003
CTLA-4: new insights into its biological function and use in tumor immunotherapy
2002 StandoutNobel
Cervical cancer vaccines: Emerging concepts and developments
2001
Adoptive immunotherapy for cancer: harnessing the T cell response
2012
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
2008
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
CTLA-4 Blockade Reverses CD8+ T Cell Tolerance to Tumor by a CD4+ T Cell– and IL-2-Dependent Mechanism
1999
Strategies for immunotherapy of cancer
2000
Human tumor antigens for cancer vaccine development
1999
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Cytokines in cancer pathogenesis and cancer therapy
2004
NY‐ESO‐1: Review of an Immunogenic Tumor Antigen
2006
Restoring function in exhausted CD8 T cells during chronic viral infection
2005 StandoutNatureNobel
Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells
2001
Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks
2020 StandoutNobel
Spinning molecular immunology into successful immunotherapy
2002
Cytokine-secreting tumor cell vaccines
2000
CD4 + T Cell–Mediated Tumor Rejection Involves Inhibition of Angiogenesis that Is Dependent on IFNγ Receptor Expression by Nonhematopoietic Cells
2000
Efficient nonviral transfection of dendritic cells and their use for in vivo immunization
2000
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
2012
CD4+ T Cells Cooperate With Macrophages for Specific Elimination of MHC Class II-Negative Cancer Cells
2007
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Cancer-related inflammation
2008 StandoutNature
Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine
2003
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
2015
Lysosome-targeting chimaeras for degradation of extracellular proteins
2020 StandoutNatureNobel
Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity
1999
Primary Antitumor Immune Response Mediated by CD4+ T Cells
2005
Dendritic cells transduced with TAT protein transduction domain‐containing tyrosinase‐related protein 2 vaccinate against murine melanoma
2003
Cancer immunotherapy with mRNA‐transfected dendritic cells
2004
TMEM41B Is a Pan-flavivirus Host Factor
2020 StandoutNobel
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
2014
Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance
1999
High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells
2004
Cross-Priming of Naive Cd8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells
2000
Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
2000
In vivoblockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
1999 StandoutNobel
Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules
2004
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
A Spontaneously Arising Pancreatic Tumor Does Not Promote the Differentiation of Naive CD8+ T Lymphocytes into Effector CTL
2004
B7x: A widely expressed B7 family member that inhibits T cell activation
2003 StandoutNobel
The Detection and Discovery of Glycan Motifs in Biological Samples Using Lectins and Antibodies: New Methods and Opportunities
2015
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Nitric oxide and the immune response
2001 Standout
Melan-A/MART-1-Specific CD4 T Cells in Melanoma Patients: Identification of New Epitopes and Ex Vivo Visualization of Specific T Cells by MHC Class II Tetramers
2006
Workshop R: Tumor Immunology, Abstract R1 bis R30
2001
Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor Immunity
2000
Production of IL-12 by Human Monocyte-Derived Dendritic Cells Is Optimal When the Stimulus Is Given at the Onset of Maturation, and Is Further Enhanced by IL-4
2001
Lack of a role for transforming growth factor-β in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation
2001 StandoutNobel
Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine
2001 StandoutNobel
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
2015
Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice
2002 StandoutNobel
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
2001 StandoutNobel
Glycocapture‐based proteomics for secretome analysis
2012
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer
2001
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
Phenotype and Homing of CD4 Tumor-Specific T Cells Is Modulated by Tumor Bulk
2005
Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance
2002 StandoutNobel
CD4+T cells eliminate MHC class II-negative cancer cellsin vivoby indirect effects of IFN-γ
1999
The future of immune checkpoint therapy
2015 StandoutScienceNobel
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
2007 StandoutNobel
Dendritic Cells Charged with Apoptotic Tumor Cells Induce Long-Lived Protective CD4+ and CD8+ T Cell Immunity against B16 Melanoma
2003 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
CD4 cells can be more efficient at tumor rejection than CD8 cells
2007
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells
2000 StandoutNobel
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy
2001 StandoutNobel
Induction of Vigorous Helper and Cytotoxic T Cell as well as B Cell Responses by Dendritic Cells Expressing a Modified Antigen Targeting Receptor-Mediated Internalization Pathway
2000
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
2008 StandoutNobel
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
2000
CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination
2003
Cd40-Independent Pathways of T Cell Help for Priming of Cd8+ Cytotoxic T Lymphocytes
2000
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Chemical Glycoproteomics
2016 StandoutNobel
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
1999 StandoutNobel
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy
1999 StandoutNobel
Works of Kenneth E. Hung being referenced
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
2012
In vivo wide-area cellular imaging by side-view endomicroscopy
2010
Low‐volume, high‐throughput sandwich immunoassays for profiling plasma proteins in mice: Identification of early‐stage systemic inflammation in a mouse model of intestinal cancer
2007
Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine
2000
The Central Role of CD4+ T Cells in the Antitumor Immune Response
1998
Mass Spectrometry-Based Study of the Plasma Proteome in a Mouse Intestinal Tumor Model
2006